NEWS・COLUMN
We send the latest information from SMC Laboratories.
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept …
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. &nb…
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), a…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints u…
September is World Alzheimer’s Month!
In recognition of September 21st being World Alzheimer’s Day, why don’t we deepen our understandin…
July 28th is World Hepatitis Day!
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help …
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis…
Introduction of the paper using our UUO model
We would like to introduce a paper published by our client using Chronic kidney disease model. &…
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunct…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related de…